A quick introduction to EDRN, its organization, and more.
In the 19th century, pathologists used the newly invented microscope to investigate the nature of cancer as well as other diseases. Along with improvements in tissue processing, the microscope took pathologists from gross anatomy to microscopic analysis, which eventually led to a new pathology. This new pathology culminated in Virchow’s concept that the fundamental changes in disease can be attributed to alterations in the cells of the body. The application of molecular technologies with minimally intrusive surgical techniques has laid the foundation for a revolutionary leap in the science of screening, early diagnosis and target-based therapy for cancer. Fueled by the discovery of cancer-specific biomarkers, and aided by pathological improvements, molecular-based tests are in the not-too-distant future to perform noninvasive diagnosis on patients. The NCI’s Early Detection Research Network (EDRN) is committed to make molecular diagnostics a reality that will allow physicians to provide individualized treatment to cancer patients. The EDRN is committed to provide up-to-date information on biomarker research through this Website and scientific publications.
Chief, Cancer Biomarkers Research Group
A quick introduction to EDRN Informatics
EDRN has a number of activities in science and informatics. I invite you to explore the site and activities. I also invite you to view a video describing our leading-edge informatics program.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.